Medication info
Trinam 2.5/500 mg (Linafagliptin, Metformin)

Trinam 2.5/500 mg (Linafagliptin, Metformin)

Prescription medicationTabletOral
Ingredient · strength
Linagliptin Besylate›3.34mg / 1 tabletMetformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
Daewoong Bio Co., Ltd.
Appearance
Yellow, oval, biconvex film-coated tablet
Packaging
30 tablets/bottle, 60 tablets/bottle
Approval status
Active

MFDS item code 202401054 · Approved 2024.04.30

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medication should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: linagliptin 2.5 mg (linagliptin besilate 3.34mg) and metformin 1000 mg twice daily. This medication should be administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients who have not previously received drug therapy for diabetes and for whom adequate glycemic control cannot be achieved with monotherapy, the initial dose of this medication is 1 tablet of 2.5/500 mg twice daily. The dose may be increased to 1 tablet of 2.5/1000 mg twice daily. 2. Patients switching from concomitant therapy with linagliptin and metformin: Patients switching from concomitant therapy with linagliptin and metformin to this medication should take an initial dose equivalent to the doses of linagliptin and metformin they were previously taking. 3. Patients who do not achieve adequate glycemic control with concomitant insulin and metformin therapy: An initial dose equivalent to linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient’s existing metformin dose should be considered. When this medication is coadministered with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Administration with Caution in the Following Patients). No studies have evaluated the safety and efficacy of switching to this medication in patients previously treated with other oral glucose-lowering agents. Any change in the treatment regimen for type 2 diabetes may alter glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medication may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who have no other condition that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this medication because the starting dose of metformin is 500mg or 850mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medication must be discontinued immediately. Patients with hepatic impairment This medication should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Do not administer to the following patients).

Ingredients

Manufacturer
Daewoong Bio Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication is used to assist type 2 diabetes patients who are using both Linafagliptin and Metformin in managing their blood sugar levels, complementing their diet and exercise regimen. Therefore, it can significantly help in effectively managing blood sugar levels.

How to take

Adult dose

The dose of this medication should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: linagliptin 2.5 mg (linagliptin besilate 3.34mg) and metformin 1000 mg twice daily. This medication should be administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients who have not previously received drug therapy for diabetes and for whom adequate glycemic control cannot be achieved with monotherapy, the initial dose of this medication is 1 tablet of 2.5/500 mg twice daily. The dose may be increased to 1 tablet of 2.5/1000 mg twice daily. 2. Patients switching from concomitant therapy with linagliptin and metformin: Patients switching from concomitant therapy with linagliptin and metformin to this medication should take an initial dose equivalent to the doses of linagliptin and metformin they were previously taking. 3. Patients who do not achieve adequate glycemic control with concomitant insulin and metformin therapy: An initial dose equivalent to linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient’s existing metformin dose should be considered. When this medication is coadministered with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Administration with Caution in the Following Patients). No studies have evaluated the safety and efficacy of switching to this medication in patients previously treated with other oral glucose-lowering agents. Any change in the treatment regimen for type 2 diabetes may alter glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medication may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who have no other condition that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this medication because the starting dose of metformin is 500mg or 850mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medication must be discontinued immediately. Patients with hepatic impairment This medication should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Do not administer to the following patients).

Precautions

This medication consists of two main ingredients and helps in controlling blood sugar. However, this medication may cause serious side effects, such as lactic acidosis, so it should not be administered to patients with poor kidney function or certain heart or liver disorders. It is also advisable for pregnant or breastfeeding women and patients with very poor nutritional status or acute illnesses not to use this medication. Before starting this medication, kidney function must be tested and regularly monitored during treatment. There is a risk of hypoglycemia, so caution is required when used with other hypoglycemic agents or insulin, and dose adjustments may be necessary as needed. If symptoms such as persistent abdominal pain, muscle weakness, difficulty breathing, or coma occur, it is essential to inform healthcare professionals immediately. Additionally, rare side effects such as acute pancreatitis or blistering dermatitis similar to epidermolysis bullosa may occur; thus, if any suspicious symptoms arise during the medication, it should be discontinued immediately and consult with a specialist. This medication may lower vitamin B12 levels, so it is advisable to regularly monitor vitamin B12 levels with long-term use. There may be interactions when taken with certain other medications, so any other medications the patient is taking should be reported to a doctor or pharmacist. This medication is not recommended for children and adolescents as its safety and efficacy have not been sufficiently established. Elderly patients should use this medication with caution, as decreased kidney function is common, and regular kidney function tests are necessary. Lastly, this medication should be avoided during pregnancy and is not recommended during breastfeeding. There is insufficient research regarding the effects of this medication on driving or operating machinery, so caution is advised.

Side effects

  • Lactic acidosis
  • hypoglycemia
  • taste disorders
  • cough
  • anorexia
  • diarrhea
  • constipation
  • nausea
  • pancreatitis
  • vomiting
Show 17 more
  • abdominal pain
  • formation of oral ulcers
  • abnormal liver function tests
  • hepatitis
  • pruritus
  • erythema
  • rash
  • vesicular pemphigoid-like lesions
  • severe and disabling arthralgia
  • rhabdomyolysis
  • increased lipase
  • increased amylase
  • nasopharyngitis
  • hypersensitivity
  • angioedema
  • urticaria
  • decreased and deficient vitamin B12

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air and moisture, so it should be stored in a tightly sealed container. It is best to maintain a storage temperature between 1 degree and 30 degrees Celsius, as this helps preserve the medication's effectiveness.

Appearance and packaging

Appearance

Yellow, oval, biconvex film-coated tablet

Package unit

30 tablets/bottle, 60 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.